Angiographic and Optical Coherence Tomography Insights into Bioresorbable Scaffold Thrombosis: Single-Center Experience by Karanasos, A. (Antonios) et al.
1Metallic drug-eluting stents (DESs) are the current stan-dard for invasive treatment of coronary artery disease. 
However, metallic DES have been associated with late com-
plications such as neoatherosclerosis and incomplete heal-
ing that can lead to failure even at long-term follow-up.1–3 
Bioresorbable vascular scaffolds (BVSs) are a new treatment 
for coronary artery disease that could potentially alleviate 
such problems.4,5 To date, bioresorbable scaffolds have been 
evaluated in first-in-man or highly selected study cohorts with 
simple lesions in low-risk patient populations,4–7 whereas vas-
cular response in lesions of real-world patients might differ. 
As BVSs are being increasingly used in more complex lesions, 
several cases of BVS thrombosis have been reported.8–10
In metallic DES, intravascular imaging has elucidated patho-
physiologic mechanisms of stent thrombosis, underscoring the 
significance of procedural factors such as inadequate stent expan-
sion and vascular trauma for acute thrombosis11,12 or delayed heal-
ing and neoatherosclerosis for late thrombosis.1,2 Whether BVS 
thrombosis is amenable to the same factors remains unknown.
We aimed to present angiographic and optical coherence 
tomography (OCT) findings in a series of patients with defi-
nite bioresorbable scaffold thrombosis treated in our catheter-
ization laboratory and compare them with a control group of 
patients with definite metallic stent thrombosis.
Methods
Study Population
The everolimus-eluting BVS (Absorb; Abbott Vascular, Santa Clara, 
CA) has been used in clinical trials in our center since 2006.4–7 Since 
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2  Karanasos et al  OCT Findings in BVS Thrombosis 
September 2012, Absorb BVS was approved for commercial use in 
Netherlands and has been used in our center also in more complex 
patients and lesions, while outcomes of these patients are recorded 
in the Expanded Clinical Use of Everolimus Eluting Bioresorbable 
Vascular Scaffolds for Treatment of Coronary Artery Disease (BVS-
Expand) and Everolimus-Eluting Bioresorbable Vascular Scaffolds 
for Treatment of Patients Presenting With ST-Segment–Elevation 
Myocardial Infarction (BVS-STEMI) registries.13,14 Up to June 1, 
2014, a total of 733 everolimus-eluting BVS had been implanted in 
469 patients in our center.
Since 2006 and up to June 2014, 14 patients were admitted to 
our laboratory because of definite BVS thrombosis. Definite BVS 
thrombosis was identified using the Academic Research Consortium 
definition requiring both angiographic evidence of scaffold thrombo-
sis (including 5-mm edge segments) and clinical evidence of acute 
coronary syndrome and were classified as acute, subacute, late, or 
very late.15 Treatment of BVS thrombosis, including thrombus aspira-
tion or invasive imaging, was performed at the operator’s discretion. 
All patients have provided informed consent.
To understand potential differences and similarities between BVS 
and metallic stent thrombosis, we used consecutive patients with 
definite metallic stent thrombosis as control. Between September 1, 
2012 and June 1, 2014, 55 patients presented with definite metallic 
stent thrombosis. We excluded patients with stent thrombosis in left 
main or in graft (n=4), as these typically large vessels are not suited 
for BVS with its currently limited diameter range, and patients with 
very late stent thrombosis >2 years since implantation (n=36), as the 
available follow-up period in BVS does not allow a meaningful com-
parison of very late thrombosis at that interval. Thus, 15 patients with 
definite metallic stent thrombosis were included as control (2 acute, 4 
subacute, 5 late, and 4 very late between 1 and 2 years).
Angiographic Analysis
Angiographic analysis was performed for baseline implantation and 
for stent/scaffold thrombosis, including quantitative coronary angiog-
raphy and assessment of intraprocedural complications. Incomplete 
lesion coverage (also called geographical miss) was defined as the 
longitudinal mismatch between implantation site and diseased coro-
nary segment or coronary segment subjected to balloon dilatation, and 
its identification required a consensus characterization by 2 observers 
that reviewed the baseline angiography, applying established meth-
odology.16 Angiographic analysis at the event included assessment of 
thrombolysis in myocardial infarction flow grade, thrombus burden,17 
and quantitative coronary angiography measurements.
OCT Image Acquisition
OCT was performed at the operator’s discretion, after thrombus as-
piration, in 9 patients with BVS thrombosis and in 5 patients with 
metallic stent thrombosis. OCT acquisition was performed with the 
Lightlab/St Jude (C7XR/Illumien, St Jude/Lightlab, St Paul, MN) or 
the Terumo Lunawave (Terumo Corporation, Tokyo, Japan) frequen-
cy-domain imaging systems, as previously described.4,14
OCT Image Analysis
OCT image analysis was performed offline in 1-mm intervals within 
the treated segment, including proximal and distal 5-mm long edge seg-
ments, after excluding frames with <75% lumen contour visibility, as 
previously described.1,7,14 Scaffold struts were defined malapposed in the 
absence of contact with the vessel wall, whereas metallic stent struts were 
malapposed when the distance of the adluminal strut reflection from the 
vessel wall exceeded the nominal strut thickness (metal backbone plus 
coating). These definitions do not include struts in front of side-branch-
es or their ostium (polygon of confluence), which are defined as side-
branch–related struts. Intraluminal struts belonging to adjacent clusters 
of apposed struts in overlapping scaffolds were not considered malap-
posed. Thrombus was defined as irregular endoluminal or mural mass 
and scaffold discontinuity (in BVS) as struts overhanging each other at 
the same angular sector, with or without malapposition, or isolated struts 
at the luminal center without obvious connection to other surrounding 
struts,7,18 further classified as fracture (present at baseline and follow-up) 
or late discontinuity (present only at follow-up). OCT findings in BVS 
thrombosis were compared between frames with and without thrombus.
Statistical Analysis
All analyses were performed with SPSS 20.0 (IBM, Chicago, IL). 
Continuous variables are presented as mean±SD, median [inter-
quartile range], or estimated means (95% confidence interval), 
whereas categorical variables are reported as count and percentages. 
Differences in continuous baseline or angiographic variables were 
assessed with t test, whereas in categorical variables with the χ2 or 
Fisher exact test. Differences in OCT variables were assessed with 
Mann–Whitney and paired comparisons with Wilcoxon, because of 
the small sample size and skewed nature of these variables. Frame- or 
strut-level analysis was performed with mixed linear or logistic re-
gression, as struts are clustered within each frame within each patient. 
Strut-level malapposition was assessed by mixed logistic regression 
using within-frame and within-patient intercepts as random effects. 
Frame-level differences were assessed with mixed linear or logistic 
regression analysis using within-patient intercepts as random effect. 
All P values are 2-sided with a value <0.05 indicating significance.
Results
Baseline Characteristics and Concomitant Therapy
Baseline characteristics for BVS (n=14) and metallic stents 
(n=15) are reported in Table 1. There were no significant differ-
ences in baseline characteristics with the exception of a higher 
proportion of men in BVS (100% versus 67%; P=0.042).
At the time of BVS thrombosis, 5 patients were not receiv-
ing dual antiplatelet therapy (DAPT) (2 with premature dis-
continuation <1 year and 3 with planned discontinuation >1 
year). In three patients, DAPT discontinuation had occurred 
the week preceding the event. In metallic stents, complete 
DAPT discontinuation <1 year was confirmed in 1 patient and 
suspected in 2, whereas 4 patients with very late thrombosis 
after 1 year were only receiving aspirin.
WHAT IS KNOWN
•	Bioresorbable scaffolds are a new treatment for 
coronary artery disease with a favorable long-term 
healing response that could potentially alleviate 
long-term complications of metallic stents such as 
neoatherosclerosis and incomplete healing.
•	Several real-world registries have demonstrated 
relatively high rates of scaffold thrombosis, driven 
mainly by increased rates of acute and subacute scaf-
fold thrombosis.
WHAT THE STUDY ADDS
•	The main pathomechanisms for both early and late 
bioresorbable scaffold thrombosis are similar to 
those of metallic stents and consist of suboptimal 
implantation with underexpansion, malapposition, 
and incomplete lesion coverage.
•	Addition to suboptimal implantation and similar to 
metallic stents, the absence of appropriate antiplate-
let therapy administration is also an important con-
tributor to bioresorbable scaffold thrombosis.
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3  Karanasos et al  OCT Findings in BVS Thrombosis 
Angiographic and Procedural Characteristics
Angiographic and procedural characteristics of baseline 
and repeat procedure are reported in Tables 2 and 3, respec-
tively. Pre- and postdilation was used more frequently in 
Table 1. Clinical and Demographic Characteristics
BVS (n=14) Metal (n=15) P Value
Age, y 60.2±10.5 64.2±11.6 0.35
Male, n (%) 14 (100) 10 (66.7) 0.042
Type, n (%) 0.70
  Acute 4 (28.6) 2 (13.3)
  Subacute 2 (14.3) 4 (26.7)
  Late 5 (35.7) 5 (33.3)
  Very late 3 (21.4) 4 (26.7)
Time to event, d 152.6±210.1 232.0±237.9 0.35
Clinical syndrome (baseline) 0.79
  Stable angina, n (%) 5 (35.7) 3 (20.0)
  Unstable angina, n (%) 1 (7.1) 2 (13.3)
  NSTEMI, n (%) 3 (21.4) 4 (26.7)
  STEMI, n (%) 5 (35.7) 6 (40.0) …
Clinical syndrome (scaffold/stent thrombosis) 0.48
  UA, n (%) 0 (0) 1 (6.7)
  NSTEMI, n (%) 7 (50.0) 5 (33.3)
  STEMI, n (%) 7 (50.0) 9 (60.0)
Antiplatelet therapy at scaffold/stent 
thrombosis*
  Aspirin, n (%) 11 (78.6) 12 (92.3) 0.99
  P2Y12 inhibitor, n (%) 0.58
   Clopidogrel 3 (21.4) 5 (38.5)
   Prasugrel 5 (35.7) 3 (23.1)
   Ticagrelor 1 (7.1) 0 (0)
  Oral anticoagulation, n (%) 3 (21.4) 1 (6.7) 0.33
CAD risk factors
  Hypertension, n (%) 9 (64.3) 5 (35.7) 0.26
  Dyslipidemia, n (%) 6 (42.9) 7 (50.0) 0.99
  Diabetes mellitus, n (%) 1 (7.1) 6 (42.9) 0.08
  Smoking, n (%) 6 (42.9) 2 (14.3) 0.21
  Family history of CAD, n (%) 5 (35.7) 5 (35.7) 0.99
Comorbidities
  Prior cerebrovascular accident, n (%) 3 (21.4) 2 (13.3) 0.60
  Peripheral vascular disease, n (%) 1 (7.1) 0 (0) 0.99
  Kidney disease, n (%) 0 (0.0) 2 (14.3) 0.48
  Prior MI, n (%) 2 (14.3) 5 (35.7) 0.39
  Prior PCI, n (%) 2 (14.3) 4 (28.6) 0.65
  Prior CABG, n (%) 0 (0.0) 0 (0) …
  COPD, n (%) 1 (7.1) 1 (7.1) 0.99
Values are presented as mean±SD or n (%). BVS indicates bioresorbable 
vascular scaffold; CABG, coronary artery bypass graft; CAD, coronary artery 
disease; COPD, chronic obstructive pulmonary disease; MI, myocardial 
infarction; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, 
percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial 
infarction; and UA, unstable angina.
*For 2 patients in the metallic stent group, poor compliance was suspected 
but not confirmed.
Table 2. Angiographic and Procedural Characteristics at 
Baseline Implantation
Angiographic Characteristics BVS (n=14)
Metal 
(n=15)
P 
Value
Vessel, n (%) 0.37
  LAD 9 (64.3) 6 (40.0)
  LCx 3 (21.4) 4 (26.7)
  RCA 2 (14.3) 5 (33.3)
Bifurcation 3 (21.4) 4 (26.7) 0.99
Ostial LAD/LCx lesion 6 (42.9) 5 (33.3) 0.71
AHA/ACC classification 0.17
  A/B1 4 (28.6) 1 (6.7)
  B2/C 10 (71.4) 14 (93.3)
Preprocedure
  TIMI flow grade, n (%) 0.57
   0 5 (35.7) 5 (33.3)
   1 0 (0) 2 (13.3)
   2 1 (7.1) 1 (6.7)
   3 8 (57.1) 7 (46.7)
  Total occlusion (n=10)
   RVD, mm 2.98±0.22 2.66±0.59 0.30
  Non-total occlusion (n=19)
   RVD, mm 2.61±0.35 2.60±0.66 0.95
   Minimal lumen diameter, mm 0.94±0.26 0.96±0.29 0.89
   Diameter stenosis, % 64.1±9.8 61.8±10.9 0.64
   Lesion length, mm 19.38±9.04 24.16±10.72 0.25
Postprocedure
  TIMI flow grade, n (%) 0.99
   0 0 (0) 0 (0)
   1 0 (0) 0 (0)
   2 0 (0) 1 (7.1)
   3 14 (100) 13 (92.9)
  RVD, mm 2.62±0.33 2.56±0.59 0.71
  Minimal lumen diameter, mm 2.32±0.22 2.23±0.36 0.44
  Diameter stenosis, % 10.9±9.5 11.7±10.5 0.82
  Acute gain, mm 1.29±0.38 1.45±0.35 0.35
  Dissection, n (%) 2 (14.3) 3 (21.4) 0.99
  Side-branch occlusion 1 (7.1) 1 (7.1) 0.99
Procedural data
  Predilation, n (%) 13 (92.9) 7 (50.0) 0.033
  Postdilation, n (%) 7 (50.0) 0 (0) 0.006
  Thrombus aspiration, n (%) 4 (28.6) 5 (35.7) 0.99
  OCT guidance, n (%) 5 (35.7) 0 (0) 0.041
  Overlap, n (%) 3 (21.4) 4 (26.7) 0.99
  Bifurcation intervention, n (%) 0.99
   T-stenting 1 (7.1) 1 (6.7)
   Balloon dilation of side-branch ostium 1 (7.1) 1 (6.7)
  Mean scaffolds/stents per patient, n 1.4±0.6 1.4±0.5 0.84
  Total scaffold/stent length per patient, mm 28.57±14.56 30.29±15.91 0.77
  Mean scaffold/stent diameter per patient, mm 3.18±0.27 2.90±0.47 0.06
All values presented as n (%) or mean±SD. ACC indicates American College 
of Cardiology; AHA, American Heart Association; BVS, bioresorbable vascular 
scaffold; LAD, left anterior descending artery; LCx, left circumflex artery; OCT, 
optical coherence tomography; RCA, right coronary artery; RVD, reference 
vessel diameter; and TIMI, thrombolysis in myocardial infarction.
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4  Karanasos et al  OCT Findings in BVS Thrombosis 
BVS compared with metallic stents (predilation: 92.9% 
versus 50.0%; P=0.033 and postdilation: 50.0% versus 0%; 
P=0.006), with a trend for higher scaffold diameter in BVS 
(3.18±0.27 versus 2.90±0.47; P=0.06). OCT post implanta-
tion had been performed in 5 of 14 patients in BVS and in 
none of the metallic stents.
Incomplete lesion coverage was observed in four BVS 
cases, and in one case with metallic stent. Two patients 
with BVS had an angiographically visible edge dissection 
(one proximal, one distal) after baseline implantation, left 
untreated.
OCT Findings
OCT at thrombosis was performed in 9 of 14 patients with 
BVS and in 5 of 15 patients with metallic stents. There was 
no significant difference in OCT findings between BVS and 
metallic stent thrombosis (Table 4). In (very) late thrombosis, 
the incidence of malapposed struts was 1.9%±2.2% for BVS 
versus 5.6%±6.2% for metallic stents (P=0.31), and malappo-
sition distance 486±225 μm for BVS versus 265±151 μm for 
metallic stents (P=0.17).
In BVS thrombosis, frames with thrombus had lower 
lumen (4.35 mm2 [2.61–6.08 mm2] versus 5.84 mm2 [4.11–
7.58 mm2]; P<0.001) and scaffold area (7.63 mm2 [6.32–8.95 
mm2] versus 8.14 mm2 [6.83–9.46 mm2]; P<0.001) com-
pared with frames without thrombus (Table I in the Data 
Supplement). No difference was found in frame-level malap-
position incidence (P=0.75), whereas malapposition area was 
numerically higher in frames with thrombus, without reaching 
significance (1.54 mm2 [0–3.44 mm2] versus 0.44 mm2 [0.00–
6.70 mm2]; P=0.18).
Patient-Specific Substrates of Thrombosis
Tables II and III in the Data Supplement present patient-spe-
cific clinical, procedural, angiographic and OCT characteris-
tics in BVS thrombosis.
(Sub)acute Thrombosis
In (sub)acute scaffold thrombosis, suboptimal implantation 
was the main mechanism. Incomplete lesion coverage was 
observed in three patients (Figure I in the Data Supplement), 
either because of mismatch of the predilated segment and the 
scaffolded segment or because of incomplete coverage of the 
thrombosed segment in ST-segment–elevation myocardial 
infarction (Figure 1). In 2 cases with BVS implantation in 
ostial left anterior descending artery, angiography demon-
strated scaffold protrusion into left main suggesting malap-
position, also with underexpansion in one. Finally, in 1 case, 
thrombus was observed in a long overlap segment (7 mm by 
Table 3. Angiographic Characteristics at Thrombosis
Angiographic Characteristics BVS (n=14) Metal (n=15) P Value
TIMI flow grade, n (%) 0.47
  0 9 (64.3) 10 (66.7)
  1 2 (14.3) 3 (20.0)
  2 2 (14.3) 0 (0)
  3 1 (7.1) 2 (13.3)
Thrombus burden index, n (%) 0.47
  0 0 (0) 0 (0)
  1 0 (0) 0 (0)
  2 2 (14.3) 1 (6.7)
  3 3 (21.4) 2 (13.3)
  4 0 (0) 2 (13.3)
  5 9 (64.3) 10 (66.7)
Total occlusion (n=19)
  RVD, mm 2.93±0.32 2.37±0.69 0.042
Non-total occlusion (n=10)
  RVD, mm 2.42±0.66 2.61±0.36 0.59
  Minimal lumen diameter, mm 0.90±0.17 0.94±0.97 0.93
  Diameter stenosis, % 60.0±15.0 66.0±33.5 0.73
All values presented as n (%) or mean±SD. BVS indicates bioresorbable 
vascular scaffold; RVD, reference vessel diameter; and TIMI, thrombolysis in 
myocardial infarction.
Table 4. OCT Findings at Thrombosis
BVS (n=9) Metal (n=5) P Value
Baseline characteristics in OCT subgroup
  Age, y 60.3 [53.1–67.3] 64.0 [59.0–73.0] 0.44
  Male, n (%) 9 (100) 3 (60.0) 0.11
Type, n (%) 0.40
  Acute 1 (11.1) 0 (0)
  Subacute 1 (11.1) 2 (40.0)
  Late 5 (55.6) 3 (60.0)
  Very late 2 (22.2) 0 (0)
  Time to event, d 129.0 [24.5–319.5]139.0 [6.5–227.5] 0.99
OCT variables
  Analyzed struts, n 222 [76.5–310.5] 202 [81.5–514.5] 0.80
  Minimum lumen area, mm2 1.87 [0.92–3.23] 1.42 [0.98–3.25] 0.90
  Mean lumen area, mm2 4.77 [3.72–6.83] 5.33 [3.87–5.72] 0.90
  Minimum scaffold/ 
stent area, mm2
6.88 [5.10–7.24] 4.87 [2.97–5.72] 0.07
  Mean scaffold/stent area, mm2 7.59 [6.86–8.95] 6.49 [5.10–7.23] 0.11
  Ratio of minimum scaffold/
stent area to reference area
0.93 [0.73–1.12] 0.82 [0.52–1.36] 0.54
  Ratio of minimum scaffold/
stent diameter to nominal 
diameter
0.87 [0.84–0.89] 0.83 [0.66–0.89] 0.53
  Malapposition area, mm2 0.13 [0.04–0.26] 0.05 [0–0.31] 0.86
  Mean neointimal/attached 
thrombus area, mm2
1.70 [1.28–2.63] 1.48 [0.93–2.19] 0.34
  Malapposed struts, % 2.50±3.27 4.63±4.70 0.48*
  Malapposition distance, μm 293±257 287±271 0.36*
  Scaffolds/stents with any 
malapposed strut, n (%)
5 (55.6) 4 (80.0) 0.58
  Scaffolds/stents with >5% 
malapposed struts, n (%)
2 (22.2) 1 (20.0) 0.99
  Thrombus, n (%) 8 (88.8) 5 (100) 0.99
  Scaffold discontinuity, n (%) 2 (22.2)
Values presented as n (%), median [IQR], or mean±SD. BVS indicates 
bioresorbable vascular scaffold; IQR, interquartile range; and OCT, optical 
coherence tomography.
*P values calculated with multilevel regression using within-patient and 
within-frame intercepts as random effects.
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5  Karanasos et al  OCT Findings in BVS Thrombosis 
OCT), together with compact fibrin and Zahn-lines in aspi-
rate histology (Figure 2), despite good expansion and apposi-
tion. In metallic stents, (sub)acute thrombosis was attributed 
to edge dissections in 3 cases, strut protrusion into left main 
with associated malapposition in 1 case, and extensive under-
expansion in 1 case (minimal stent area, 1.19 mm2). In 1 case, 
there were no findings suggesting suboptimal implantation, 
but there was suspicion of poor compliance with DAPT.
(Very) Late Thrombosis
In 1 case, despite meeting Academic Research Consortium 
criteria for definite thrombosis, OCT disclosed the absence of 
thrombus and occlusive edge restenosis as substrate (Figure 
Figure 1. Acute thrombosis because of incomplete lesion coverage. A, Preprocedural and (B) postprocedural angiogram after bioresorb-
able vascular scaffold implantation in a ST-segment–elevation myocardial infarction patient undergoing primary percutaneous coronary 
intervention. Mild haziness at the proximal edge postprocedure (arrow). C, Angiogram at event after thrombus aspiration. Red and white 
thrombus at the proximal scaffold segment (D) and proximal edge segment (E) extending >5 mm. The thrombus is overlying a thin-cap 
fibroatheroma, with possible rupture (arrow). Thrombus aspirate histology (F and G) demonstrates platelet-rich thrombus.
Figure 2. Subacute bioresorbable vascular scaffold thrombosis in extensive strut overlap. A, Preprocedural and (B) postprocedural angio-
gram at baseline. C, Angiogram at event showing contrast deficit in the scaffolded segment. D and E, Optical coherence tomography 
demonstrates thrombus mainly at the overlap (D). F and G, Thrombus aspirate histology shows compact fibrin with Zahn-lines (arrows).
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6  Karanasos et al  OCT Findings in BVS Thrombosis 
II in the Data Supplement). In most patients, (very) late BVS 
thrombosis was observed in the presence of regional subop-
timal flow conditions, such as strut malapposition, scaffold 
fracture, and underexpansion. Four of 7 patients with (very) 
late BVS thrombosis undergoing OCT had malapposed struts. 
In 2 patients, malapposition was observed in the absence 
of scaffold discontinuity (Figure 3), also with underexpan-
sion and restenosis in one of them. In the other 2 patients, 
malapposition was observed because of strut discontinuity: 1 
with late discontinuity and intraluminal thrombus,19 possibly 
resulting from balloon dilation of the scaffolded segment after 
the index procedure, whereas acute fracture had been detected 
in a second case. In this second case, late thrombosis occurred 
2 days after both aspirin and clopidogrel discontinuation; 
however, there was no thrombus in the fracture site, but in an 
underexpanded long overlap segment (Figure 4). In 3 cases, 
the substrate was not clearly identified: 1 very late thrombosis 
case where late discontinuity was suspected but not clearly 
identified because of thrombus (Figure III in the Data Supple-
ment), 1 very late thrombosis case with extensive baseline 
Figure 3. Late bioresorbable vascular scaffold (BVS) thrombosis and malapposition. BVS implantation in a total left anterior descending 
artery occlusion with postdilation (A), resulting in acceptable angiographic result with mild haziness (B), but residual thrombus by optical 
coherence tomography (OCT; C and D) and residual plaque burden by intravascular ultrasound (E). Postdilation was not repeated, consid-
ering the risk of side-branch occlusion. F, Angiogram at event after thrombus aspiration. G through I, OCT shows massive red thrombus, 
and late malapposition (arrows).
Figure 4. Late scaffold thrombosis after dual antiplatelet therapy discontinuation in overlapping bioresorbable vascular scaffold (BVS) 
with underexpansion. Overlapping BVS implantation in a diffuse calcified left anterior descending artery lesion (A), with acceptable angio-
graphic result (B), but underexpansion by intravascular ultrasound (C), and scaffold fracture at the proximal edge by optical coherence 
tomography (OCT; D), possibly because of deep catheter intubation. The patient experienced late thrombosis 161 days post implantation 
(E), 2 days after aspirin and clopidogrel discontinuation. OCT shows thrombosis mainly at the overlap region, with low minimal scaffold area 
(4.21 mm2; F), whereas the fracture site remains free of thrombus (G).
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malapposition (8.6% malapposed struts) and intrascaffold dis-
sections (no imaging at the event), and 1 late thrombosis case 
with T-stenting with BVS in a left anterior descending artery-
diagonal bifurcation. The 2 latter patients were not receiving 
any antiplatelet agent at the time of late scaffold thrombo-
sis. In metallic stents, late thrombosis was associated with 
malapposition in 2 cases and with strut protrusion into left 
main in another case. Complete DAPT discontinuation was 
confirmed in an additional patient and suspected in another 
with late thrombosis. In 4 patients with very late metallic stent 
thrombosis, baseline or follow-up angiography did not sug-
gest any mechanical issues, while intravascular imaging was 
not performed.
Discussion
This real-world case series provides unique insights in the 
mechanisms of BVS thrombosis. The main findings of our 
study are (1) device thrombosis remains an issue with BVS, 
with the timing of the event evenly distributed from acute to 
very late thrombosis; (2) similar to metallic stents, acute and 
subacute BVS thrombosis is predominantly associated with 
suboptimal implantation; and (3) late and very late scaffold 
thrombosis is frequently observed in the presence of regional 
suboptimal flow conditions, often in combination with cessa-
tion of DAPT.
Notwithstanding promising results from first-in-man stud-
ies showing favorable BVS long-term healing response4,7 
and clinical results comparable with metallic DES,5,6 little 
is known about vascular healing after BVS implantation in 
complex lesions. Real-world registries have reported high 
6-month BVS thrombosis rates, driven mainly by increased 
early thrombosis,8,9 implying a possible role of suboptimal 
implantation. In our series, we report on 14 cases of definite 
BVS thrombosis at different intervals since implantation and 
compare the imaging findings with a control group of metal-
lic stents with definite stent thrombosis from the same time 
period, thus providing imaging insights into this complication. 
Importantly, suboptimal implantation was identified in both 
groups in a similar extent, suggesting that achieving an opti-
mal implantation result might be more crucial than the type of 
implanted device in avoiding device thrombosis.
(Sub)acute BVS Thrombosis: Impact of Suboptimal 
Implantation
In acute and subacute BVS thrombosis, suboptimal implanta-
tion, comprising incomplete lesion coverage, malapposition, 
and underexpansion, was identified as the leading morphologi-
cal substrate. This finding is in line with established substrates 
for metallic stent thrombosis12 and confirmed by observations 
in our control group. As the current BVS generation has a 
relatively high crossing profile, BVSs require rigorous lesion 
preparation, potentially translating to higher risk for incom-
plete coverage of the injured segment, compared with direct 
stenting often applied with metallic stents. Thus, our findings 
might urge the operator to specifically ensure complete cover-
age of the lesion and injured segments, including angiographi-
cally apparent edge dissections.
Furthermore, the development of acute and subacute BVS 
thrombosis in 2 ST-segment–elevation myocardial infarction 
patients, after BVS implantation in ostial left anterior descend-
ing artery with scaffold protrusion into the left main, raises 
speculation that hemodynamic disturbances resulting from the 
protrusion and the associated malapposition could be a sub-
strate for thrombosis.20–22 This was also documented by OCT 
in 2 metallic stent thrombosis cases, suggesting a similar con-
tribution of this mechanism.
Finally, 1 case of subacute thrombosis occurred despite 
good expansion and apposition, in the presence of long strut 
overlap. The high strut thickness of Absorb BVS (150 μm) 
and bench observations of increased thrombogenicity of 
thick-strut stents which is more pronounced at overlap sites,21 
together with histological observations of Zahn-lines in the 
aspirates, indicate a potential involvement of flow disturbances 
induced by long overlap and make a case for minimizing over-
lap length in treatment of long lesions by BVS. Whether this 
increased strut thickness could translate to increased throm-
bogenicity in vivo in the presence of an optimal implantation 
result remains unknown.
These findings underscore the significance of a meticulous 
BVS implantation technique, potentially including invasive 
imaging guidance, which has proven advantages over angi-
ography for achieving optimal lesion treatment, in terms of 
coverage and expansion.23 It is important however to note that 
imaging guidance during the procedure might drive the opera-
tor to excessive postdilation, potentially leading to scaffold 
fracture. Therefore, thorough lesion evaluation before implan-
tation might help avoid situations with pronounced mismatch 
between scaffold and artery size.
Late and Very Late BVS Thrombosis: Prominent 
Role of Suboptimal Flow Conditions
(Very) late thrombosis events in our series were attributed to 
factors potentially affecting flow conditions. These include 
underexpansion and pronounced strut protrusion into the 
lumen as a result of malapposition, bifurcation intervention, 
or strut discontinuity. Underexpansion has been identified as 
an important predictor of metallic DES thrombosis.3,12 The 
significance of optimal expansion in avoiding BVS thrombo-
sis is underscored by the finding of lower scaffold area in sites 
with thrombus compared with sites without thrombus.
The role of malapposition in late metallic DES thrombo-
sis is debated24; however, there is high prevalence in patients 
with events,1 and late malapposition in first-generation DES 
has been identified as predictor of very long-term adverse 
outcome.25 In our series, malapposition in (very) late BVS 
thrombosis (1.9±2.2%) did not differ significantly from late 
metallic stent thrombosis and was higher than the range 
reported for follow-up of second-generation metallic DES.26 
Likewise, malapposition distance (486±225 μm) was similar 
to metallic stents (265±151 μm) and at the range of previ-
ously reported values in metallic DES thrombosis (mean: 350 
μm).1 Therefore, malapposition of such extent, either persis-
tent or late-acquired, might contribute to (very) late scaffold 
thrombosis.
As opposed to metallic DES, extensive malapposition in 
BVS might also result from strut discontinuity, which was 
associated with extensive thrombosis in a very late event in our 
series, possibly triggered by DAPT cessation.19 Whether small 
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discontinuities, resulting from normal scaffold resorption, are 
associated with thrombosis is unclear. Notwithstanding this 
poorly documented association of discontinuity with throm-
bosis,18 precautionary measures such as respecting the postdi-
lation limits and cautious catheter recrossing or reintervention 
at later time points should be considered.
Role of DAPT Discontinuation
In addition to suboptimal implantation, DAPT cessation 
seems to play a role in BVS thrombosis, as in metallic DES.27 
In 3 cases, there was a close temporal association of DAPT 
cessation with clinical manifestation of BVS thrombosis, 
tracking with observations in first-generation metallic DES, 
where scheduled P2Y12 inhibitor withdrawal was associated 
with increased ischemic events.28 As we assume concomitant 
suboptimal flow conditions in these patients, caused by under-
expansion or extensive malapposition, we speculate on a pos-
sible synergistic effect of these factors in scaffold thrombosis. 
Consequently, these observations might raise questions about 
the need for platelet reactivity testing in patients with complex 
procedures or where optimal expansion cannot be achieved. 
Furthermore, the impact of DAPT cessation could be more 
pronounced when both aspirin and P2Y12 inhibitor are with-
drawn in patients receiving chronic oral anticoagulation, as 
in 3 patients in our BVS series. Therefore, considering our 
observations of ongoing thrombotic risk even beyond 1 year, 
BVS implantation in such patients should be accompanied by 
adequate antiplatelet therapy or avoided in case of high bleed-
ing risk.
Clinical Implications
Collectively, our findings underscore the significance of an 
optimal implantation result for minimizing the incidence of 
BVS thrombosis. Intravascular imaging at baseline could 
allow for early recognition and treatment of incomplete lesion 
coverage, better procedural planning in ostial lesions,29 and 
optimal BVS sizing and postdilating, thus avoiding underex-
pansion23 or scaffold fracture. Moreover, similar to metallic 
DES, proper DAPT administration must be emphasized.27 
Therefore, future studies should focus on optimal DAPT dura-
tion in patients with BVS, whereas platelet reactivity testing 
might be considered in selected patients with suboptimal 
implantation or complex intervention. Finally, in patients con-
comitantly receiving anticoagulants, administration of at least 
1 antiplatelet agent until resorption or for life should be con-
sidered, pending appropriate studies.
Limitations
This study is focusing on a mechanistic understanding of BVS 
thrombosis. The study design and its single-center nature pre-
clude firm estimations of BVS thrombosis incidence and pre-
dictors in real-world populations, considering the inclusion 
of patients treated for BVS thrombosis in our center, leading 
to possible underestimation. As OCT was not systematically 
performed, it was only available for 9 of 14 patients. Rou-
tine OCT use could have provided further insights into the 
pathomechanisms of BVS thrombosis, whereas the small 
number of patients undergoing OCT might be a limitation in 
the mixed model analysis of OCT variables. Moreover, the 
lack of a control group of BVS without thrombosis precludes 
assessment of morphological predictors of BVS thrombosis. 
Residual thrombus might have underestimated our results, 
hampering complete substrate visualization, while precluding 
coverage assessment, which is based on thickness measure-
ments for BVS, that are inaccurate in the presence of attached 
thrombus, rather than on visual confirmation of overlying 
tissue as in metallic stents.1,7 Therefore, a possible contribu-
tion of incomplete strut coverage could not be systematically 
evaluated. Finally, no platelet function tests were performed 
that could evaluate a possible contribution of increased plate-
let reactivity to BVS thrombosis.
Conclusions
Suboptimal implantation with underexpansion, malapposi-
tion, and incomplete lesion coverage comprised the main 
pathomechanisms for both early and late BVS thrombosis in 
our series, similar to metallic stent thrombosis. DAPT discon-
tinuation seems to also be a secondary contributor in several 
late events. Our observations suggest that a number of poten-
tial triggers for BVS thrombosis could be avoided and might 
warrant prospective validation.
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SUPPLEMENTAL MATERIAL 
 
Supplementary Methods 
 
Quantitative coronary angiography 
Quantitative coronary angiography was performed using CAAS 5.11 (Pie Medical Imaging, 
Maastricht, Netherlands) and included reference vessel diameter (RVD), diameter stenosis 
(DS%), and minimal lumen diameter (MLD). 
 
Histopathological analysis of thrombus aspirates 
Thrombus aspiration was attempted in thirteen cases. However, aspiration samples were 
successfully retrieved only in four (30.8%) and were collected after filtering (40μm cell strainer 
BD Biosciences), snap-frozen and stored at -80°C. Macroscopic characteristics such as color, 
size and number of particles were documented. The frozen samples were cryosectioned (5μm 
serial sections), fixed with buffered paraformaldehyde 4%, and stained with hematoxylin-eosin 
as a routine stain, rosorcin-fuchin as an elastin stain and alcian blue for proteoglycans. Polarized 
light was used to detect birefringence. 
 
  
2 
 
Supplementary Results 
Histopathological findings of thrombus aspirates 
Four thrombus aspirates were submitted for histopathology analysis. One sample did not contain 
any thrombus. One case contained only micro-thrombi [mean length 36µm (25-52μm)] without 
cellular elements. Two cases contained overt thrombi: one being platelet-rich and one containing 
compact fibrin with Zahn-lines. Eosinophilic granulocytes were observed in both but comprised 
<10% of all granulocytes, reflecting normal distribution. There was no evidence of 
hypersensitivity towards scaffold material. Vessel wall components and atheroma were not 
observed. There was no birefringence indicative of polymeric scaffold material in the aspirates. 
 
Treatment of BVS thrombosis 
At the discretion of the operator, thrombus aspiration was performed in 13/14 patients. 
Glycoprotein IIb/IIIa inhibitors were administered in 9/14 cases (64.3%). Seven of 14 patients 
were treated by implantation of a metallic DES. Two patients with edge problems were treated 
by additional BVS implantation. Four patients were treated by combination of thrombus 
aspiration and balloon dilation, while in one patient the attempt for treatment of acute thrombosis 
failed. This patient developed a large myocardial infarction (CKpeak: 4358U/L), which led to poor 
left ventricular systolic function and implantation of an implantable cardioverter-defibrillator for 
non-sustained ventricular tachycardia. In all patients, antiplatelet therapy after thrombosis was 
recommended for at least one year, continued by aspirin alone, including patients concomitantly 
receiving oral anticoagulation. 
Repeated OCT pullbacks were available for 5/7 patients that underwent additional 
metallic stent implantation, and for 1/2 patients with additional scaffold implantation for the 
3 
 
treatment of BVS failure: in these 6 patients, the mean lumen area was increased from 4.40mm² 
[2.80-6.43mm²] to 8.34mm² [7.43-8.88mm²] (p=0.028), mean scaffold area increased non-
significantly from 7.49mm² [6.99-9.29mm²] to 9.21mm² [7.51-9.89mm²]  (p=0.29), mean 
prolapse/neointimal area decreased non-significantly from 1.94mm² [1.13-2.98mm²] to 0.83mm² 
[0.47-1.22mm²] (p=0.07), and the percentage of malapposed struts was non-significantly 
decreased from 3.1% [0-6.4%] to 0.6% [0.2-1.6%] (p=0.17). 
 
Clinical outcome after treatment of BVS thrombosis 
In 11 patients, follow-up was uneventful, while 3 patients suffered a recurrent event: One patient 
died of cardiac cause 4 days after the procedure.  The second patient receiving a metallic DES 
for the treatment of BVS thrombosis, had an invasive follow-up 6 months follow-up. OCT 
showed an overall good expansion and healing result with nevertheless sporadic clusters of 
uncovered struts. This patient suffered recurrent thrombosis, one year after the initial event, and 
5 days after scheduled prasugrel discontinuation. The third patient had a repeat target vessel 
revascularization 4 months after thrombosis by coronary artery bypass graft (CABG), due to 
restenosis of the metal DES implanted for the treatment of BVS thrombosis. 
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Supplementary Tables 
Supplementary Table 1. OCT findings in BVS thrombosis in frames with and without 
thrombus 
 
Frames with 
thrombus 
(n=140) 
Frames without 
thrombus 
(n=112) 
p-value 
Lumen area, mm2 4.35 (2.61-6.08) 5.84 (4.11-7.58) <0.001* 
Scaffold area, mm2 7.63 (6.32-8.95) 8.14 (6.83-9.46) <0.001* 
Malapposition area, mm² (n=16) 1.54 (0-3.44) 0.44 (0.00-6.70) 0.18* 
Frames with malapposition, % 5.3 (1.8-15.1) 6.3 (2.0-17.9) 0.75* 
Frames with overlap, % 4.8 (1.4-15.4) 2.3 (0.5-9.3) 0.20* 
All values presented as estimated means (95% confidence intervals). 
*P-values and estimated means were calculated with multilevel regression analysis using within-
patient intercepts as random effects. 
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Supplementary Table 2. Patient-level characteristics 
 
 Baseline and procedural characteristics Scaffold thrombosis 
Case Age ACS 
Prescribed 
P2Y12 
inhibitor 
Treated 
vessel 
AHA/
ACC 
class 
Bifurcation 
Ostial 
LAD/LCx 
lesion 
No 
of 
BVS 
Total 
BVS 
length 
OCT 
guided 
Pre-
dilation 
Post-
dilation 
Type 
Time 
(days) 
ASA 
P2Y12 
inh 
OAC 
1 50 Yes clopidogrel LCX C No No 1 18 No Yes No Acute 0 Yes Yes No 
2 51 Yes ticagrelor RCA B1 No No 1 28 No Yes No Acute 0 Yes Yes No 
3 59 Yes prasugrel LAD C No No 1 18 No No No Acute 1 Yes Yes No 
4 62 Yes prasugrel LAD B1 No Yes 1 18 No Yes No Acute 1 Yes Yes No 
5 49 Yes prasugrel LAD B2 No Yes 1 18 No Yes Yes Subacute 17 Yes Yes No 
6 45 No clopidogrel LAD B2 No No 2 56 No Yes Yes Subacute 2 Yes Yes No 
7 65 Yes prasugrel LAD B2 Yes No 1 18 No Yes Yes Late 142 Yes Yes No 
8 69 Yes clopidogrel LAD C Yes Yes 3 64 Yes Yes Yes Late 47 Yes Yes No 
9 59 No prasugrel LAD C No Yes 1 28 No Yes Yes Late 112 Yes Yes No 
10 55 No clopidogrel LCX A No Yes 1 18 Yes Yes No Very late 675 Yes No No 
11 71 No clopidogrel LAD C No No 2 36 Yes Yes Yes Late 161 No No Yes 
12 62 Yes prasugrel RCA C No No 1 28 Yes Yes No Very late 478 Yes No No 
13 86 Yes clopidogrel LCX C No Yes 1 28 Yes Yes No Very late 371 No No Yes 
14 60 No clopidogrel LAD C Yes No 2 24 No Yes Yes Late 129 No No Yes 
Abbreviations: ACS=acute coronary syndrome, BVS=bioresorbable vascular scaffold, OCT=optical coherence tomography, ASA=acetylsalicylic acid, 
OAC=oral anticoagulation 
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Supplementary Table 3. Patient-level angiographic and OCT findings 
Case Type 
Time 
(days) 
Incomplete 
lesion 
coverage 
Malapposition Restenosis Discontinuity Underexpansion 
Other baseline 
findings 
Other follow-up 
findings 
Recent DAPT 
discontinuation 
DAPT 
discontinuation 
<1 year 
1 Acute 0 Dissection N/A No No No No No No No 
2 Acute 0 
Thrombosed 
segment 
Yes No No No No No No No 
3 Acute 1 
Thrombosed 
segment 
N/A No No No No No No No 
4 Acute 1 No 
Suspected 
(angio) 
No No No No No No No 
5 Subacute 17 No 
Suspected 
(angio) 
No No Suspected (angio) No No No No 
6 Subacute 2 No No No No No No 
Thrombus overlying 
extensive overlap 
region (7mm) 
No No 
7 Late 142 Dissection No Edge No No No 
Occlusive proximal 
edge restenosisNo 
no thrombus 
No No 
8 Late 47 No 
Yes (late 
malapposition) 
No No No 
Residual plaque 
burden/ residual 
thrombus 
No No No 
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9 Late 112 No Yes Yes No Yes No No No No 
10 Very late 675 No 
Yes (late 
malapposition) 
No 
Late 
discontinuity 
No No No Yes No 
11 Late 161 No Yes (Fracture) No Fracture Yes No 
Thrombus in 
underexpanded long 
overlap 
region(~5mm) 
Yes Yes 
12 Very late 478 No Possible No 
Possible late 
discontinuity 
No No No No No 
13 Very late 371 No Yes (Baseline) No No No 
Extensive intra-
scaffold 
dissections  
No Yes No 
14 Late 129 No No No No No No 
Uncovered struts 
protruding at the 
bifurcation 
No Yes 
Abbreviations: OCT=optical coherence tomography, DAPT=dual antiplatelet therapy 
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Supplementary Figures 
 
 
Supplementary Figure 1. Summary of the cases with acute thrombosis due to incomplete lesion 
coverage 
Black arrows indicate the scaffold markers and white arrows indicate the uncovered edge segment. 
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Supplementary Figure 2. Late stent thrombosis re-classified by OCT as edge restenosis resulting from 
incomplete lesion coverage. 
A. Pre-procedural and B. post-procedural angiogram at baseline showing proximal edge dissection (white 
arrow). C. Angiogram at event (142 days) shows contrast deficit at the proximal edge, extending within the 
scaffold with TIMI I flow. OCT discloses occlusive edge restenosis (D) and restenosis within the scaffold 
with layered pattern (E), without luminal thrombus. F. Angiographic review demonstrating incomplete 
lesion coverage. Black arrows indicate the scaffold markers and white arrows the uncovered edge segment. 
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Supplementary Figure 3. Very late scaffold thrombosis without definite substrate. 
BVS implantation in a proximal RCA lesion due to STEMI (A), with good post-procedural angiographic (B) 
and OCT (C-D) result. The patient suffered very late scaffold thrombosis 478 days post implantation, while 
only on aspirin (E). OCT shows suspected scaffold discontinuity (F; white arrow) and uncovered and 
possibly malapposed struts (G; yellow arrow) proximally to the thrombosed segment. 
 
